David A. Siegel Xeris Biopharma Holdings, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 23,559 shares of XERS stock, worth $67,614. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,559
Previous 10,097
133.33%
Holding current value
$67,614
Previous $22,000
140.91%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XERS
# of Institutions
133Shares Held
57MCall Options Held
126KPut Options Held
45K-
Black Rock Inc. New York, NY10.3MShares$29.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.66MShares$22 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$14.7 Million61.49% of portfolio
-
Bio Impact Capital LLC Cambridge, MA4.83MShares$13.9 Million1.75% of portfolio
-
State Street Corp Boston, MA3.26MShares$9.35 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $390M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...